Combining Ozonated Autohemotherapy with Pharmacological Therapy for Comorbid Insomnia and Myofascial Pain Syndrome: A Prospective Randomized Controlled Study
Table 2
Change of polysomnography data in the two groups.
Pretreatment
Posttreatment
1-month
6-month
valuea
Pre vs. post
Pre vs. 1-month
Pre vs. 6-month
Total sleep time (min)
Control group
355.60 ± 58.49
373.09 ± 58.74
360.58 ± 60.17
357.67 ± 63.87
<0.01
0.11
0.53
O3-AHT group
362.55 ± 58.45
415.20 ± 49.12
421.73 ± 51.86
428.62 ± 48.84
<0.01
<0.01
<0.01
valueb
0.55
<0.01
<0.01
<0.01
Sleep onset latency (min)
Control group
55.93 ± 18.15
49.55 ± 10.81
54.59 ± 14.59
53.43 ± 12.11
<0.01
0.24
0.02
O3-AHT group
54.64 ± 18.44
32.23 ± 15.58
31.85 ± 11.52
25.22 ± 9.32
<0.01
<0.01
<0.01
valueb
0.72
<0.01
<0.01
<0.01
Wake after sleep onset (min)
Control group
83.22 ± 34.24
80.15 ± 20.90
75.57 ± 24.23
78.88 ± 17.11
0.14
<0.01
0.04
O3-AHT group
86.90 ± 35.68
40.39 ± 13.04
39.76 ± 10.77
34.61 ± 12.94
<0.01
<0.01
<0.01
valueb
0.60
<0.01
<0.01
<0.01
Sleep efficiency (%)c
Control group
72.62 ± 8.89
75.26 ± 10.52
76.87 ± 8.13
73.96 ± 9.53
<0.01
<0.01
0.08
O3-AHT group
73.38 ± 12.18
87.59 ± 6.13
89.11 ± 6.12
91.45 ± 5.93
<0.01
<0.01
<0.01
valueb
0.72
<0.01
<0.01
<0.01
Number of awakenings
Control group
2.87 ± 1.85
2.88 ± 1.18
2.67 ± 1.23
2.79 ± 1.01
0.87
0.10
0.56
O3-AHT group
3.07 ± 1.95
1.52 ± 0.70
1.47 ± 0.97
1.40 ± 1.10
<0.01
<0.01
<0.01
valueb
0.60
<0.01
<0.01
<0.01
Values are the mean ± standard deviation. arepeated measures analysis of variance. bindependent-samplet-test. csleep efficiency = (total sleep time/total time in bed) × 100%. O3-AHT, ozonated autohemotherapy.